Logo image of RGC

REGENCELL BIOSCIENCE HOLDING (RGC) Stock Fundamental Analysis

NASDAQ:RGC - Nasdaq - KYG7487R1002 - Common Stock - Currency: USD

560  +118.5 (+26.84%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RGC. RGC was compared to 198 industry peers in the Pharmaceuticals industry. While RGC has a great health rating, there are worries on its profitability. RGC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RGC has reported negative net income.
In the past year RGC has reported a negative cash flow from operations.
RGC had negative earnings in each of the past 5 years.
In the past 5 years RGC always reported negative operating cash flow.
RGC Yearly Net Income VS EBIT VS OCF VS FCFRGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

The Return On Assets of RGC (-58.95%) is worse than 62.63% of its industry peers.
Looking at the Return On Equity, with a value of -61.85%, RGC is in line with its industry, outperforming 52.02% of the companies in the same industry.
Industry RankSector Rank
ROA -58.95%
ROE -61.85%
ROIC N/A
ROA(3y)-161.64%
ROA(5y)-161.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RGC Yearly ROA, ROE, ROICRGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGC Yearly Profit, Operating, Gross MarginsRGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

RGC has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGC Yearly Shares OutstandingRGC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
RGC Yearly Total Debt VS Total AssetsRGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

An Altman-Z score of 7406.22 indicates that RGC is not in any danger for bankruptcy at the moment.
RGC has a Altman-Z score of 7406.22. This is amongst the best in the industry. RGC outperforms 99.49% of its industry peers.
There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7406.22
ROIC/WACCN/A
WACCN/A
RGC Yearly LT Debt VS Equity VS FCFRGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

RGC has a Current Ratio of 19.05. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.
RGC has a better Current ratio (19.05) than 89.90% of its industry peers.
RGC has a Quick Ratio of 19.05. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.
RGC's Quick ratio of 19.05 is amongst the best of the industry. RGC outperforms 89.90% of its industry peers.
Industry RankSector Rank
Current Ratio 19.05
Quick Ratio 19.05
RGC Yearly Current Assets VS Current LiabilitesRGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for RGC have decreased strongly by -321.43% in the last year.
EPS 1Y (TTM)-321.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-172.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGC Price Earnings VS Forward Price EarningsRGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGC Per share dataRGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENCELL BIOSCIENCE HOLDING

NASDAQ:RGC (5/23/2025, 8:52:53 PM)

560

+118.5 (+26.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners0.29%
Inst Owner Change-72.02%
Ins Owners81.22%
Ins Owner Change0%
Market Cap7.29B
Analysts63.4
Price TargetN/A
Short Float %2.37%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 605.62
P/tB 605.62
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.95%
ROE -61.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-161.64%
ROA(5y)-161.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.34%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.05
Quick Ratio 19.05
Altman-Z 7406.22
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)176.78%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-172.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-335.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.88%
OCF growth 3YN/A
OCF growth 5YN/A